LOAd703 (LOKON003)
Malignant Melanoma
Phase 1/2Completed
Key Facts
About Lokon Pharma
Lokon Pharma is a clinical-stage biotech company pioneering immunostimulatory gene therapy for oncology. Its lead platform, the LOAd family of oncolytic adenoviruses, is engineered to modify the tumor microenvironment and stimulate anti-cancer immunity. The company has completed multiple Phase I/II trials in pancreatic cancer, melanoma, and other solid tumors, and has secured strategic collaborations with major pharmaceutical players like Roche. Lokon is positioning its lead candidate, LOAd703, for later-stage development, supported by FDA Fast Track Designation in pancreatic cancer.
View full company profileTherapeutic Areas
Other Malignant Melanoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Immuno-oncology Candidate | Teva | Preclinical/Phase 1 |